Beam Therapeutics Newsroom

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report

GlobeNewswireMay 14 16:00 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)

TipRanksMay 10 21:50 ET

Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones

TipRanksMay 10 01:18 ET

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)

TipRanksMay 9 08:30 ET

Beam Therapeutics Is Maintained at Equal-Weight by Barclays

Beam Therapeutics Is Maintained at Equal-Weight by Barclays

Dow JonesMay 8 14:14 ET

Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays

Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays

Dow JonesMay 8 14:14 ET

Express News | Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33

BenzingaMay 8 14:03 ET

Beam Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 50.75% Barclays $42 → $33 Maintains Equal-Weight 04/23/2024 160.39% Wedbush → $57 Reiterates Ou

BenzingaMay 8 14:02 ET

Express News | Beam Therapeutics Inc : Barclays Cuts Target Price to $33 From $42

ReutersMay 8 07:39 ET

Beam Therapeutics: A Strong Buy on Breakthrough Potential and Financial Stability

TipRanksMay 8 07:19 ET

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief

GlobeNewswireMay 8 06:30 ET

Express News | Beam Therapeutics Inc : Jefferies Cuts Target Price to $23 From $30

ReutersMay 8 00:53 ET

Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview

Yahoo FinanceMay 7 21:02 ET

Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Beam Therapeutics (BEAM)

TipRanksMay 7 13:20 ET

Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates

Beam Therapeutics (BEAM) shares slid 3.6% in recent Tuesday trading after the company reported Q1 revenue that missed analysts' estimates. The company reported a Q1 net loss Tuesday of $1.21 per dilut

MT NewswiresMay 7 10:17 ET

Beam Therapeutics | 10-Q: Quarterly report

Futu NewsMay 7 07:24 ET · Announcements

Express News | Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027

BenzingaMay 7 06:39 ET

Express News | Beam Therapeutics Q1 2024 GAAP EPS $(1.21) Beats $(1.44) Estimate, Sales $7.410M Miss $16.967M Estimate

BenzingaMay 7 06:38 ET

Express News | Beam Therapeutics Inc - Beam-301 on Track for Submission of U.S. Investigational New Drug (Ind) Application in First Half of 2024

ReutersMay 7 06:30 ET

Express News | Beam Therapeutics Inc - Cash Runway Expected to Support Operating Plans Into 2027

ReutersMay 7 06:30 ET